| Abeona Therapeutics (ABEO) | |||
|---|---|---|---|
| 3.26 0.07 (2.19%) | 04-26 16:00 | ||
| Open: | 3.2699 | Pre. Close: | 3.19 |
| High: | 3.38 | Low: | 3.2 |
| Volume: | 1,190,314 | Market Cap: | 89(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 7.46 One year: 9.87 |
| Support: | Support1: 3.05 Support2: 2.54 |
| Resistance: | Resistance1: 6.39 Resistance2: 8.45 |
| Pivot: | 6.43  |
| Moving Averages: | MA(5): 4.08 MA(20): 6.74 MA(100): 6.13 MA(250): 4.79  |
| MACD: | MACD(12,26): -0.93 Signal(12,26,9): -0.37 |
| %K %D: | %K(14,3): 2.35 %D(3): 3.90 |
| RSI: | RSI(14): 20.97 |
| 52-Week: | High: 9.01 Low: 2.83 Change(%): 6.2 |
| Average Vol(K): | 3-Month: 513 10-Days: 1247 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 3.386 - 3.402 | 3.402 - 3.417 |
| Low: | 3.161 - 3.179 | 3.179 - 3.196 |
| Close: | 3.23 - 3.26 | 3.26 - 3.287 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABEO ] has closed above bottom band by 8.7%. Bollinger Bands are 323.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 27.36 |
| % Held by Insiders | 19080000.00 |
| % Held by Institutions | 4.94 |
| Shares Short (K) | 1640 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -45910000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | 377.1 |
| Return on Equity (ttm) | -47.0 |
| Qtrly Rev. Growth | 3500000.0 |
| Gross Profit (p.s.) | -67.568 |
| Sales Per Share | -176.081 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -2.53 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -37.01 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | -0.02 |
| Price to Cash Flow | 8.62 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 1990000.000 |
